Evaluating the Effect of Oral Famotidine in Preventing Hypersensitivity Reactions in Individuals Receiving Platinum-Based Agents or Taxanes.

IF 1.4 4区 医学 Q4 ONCOLOGY Asia-Pacific journal of clinical oncology Pub Date : 2025-02-04 DOI:10.1111/ajco.14154
Faraz Tohidifar, Mohammad Mohammadzadeh, Elnaz Shaseb, Samineh Beheshtirouy, Parvin Sarbakhsh, Saba Ghaffary
{"title":"Evaluating the Effect of Oral Famotidine in Preventing Hypersensitivity Reactions in Individuals Receiving Platinum-Based Agents or Taxanes.","authors":"Faraz Tohidifar, Mohammad Mohammadzadeh, Elnaz Shaseb, Samineh Beheshtirouy, Parvin Sarbakhsh, Saba Ghaffary","doi":"10.1111/ajco.14154","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hypersensitivity reactions (HSRs), an unpredictable and sometimes harmful reaction, may hamper the effectiveness of chemotherapy and lead to the need for drug switching. The recall of ranitidine from the drug market due to the N-nitrosodimethylamine production necessitates the identification of a proper alternative for the prevention of HSRs. Our study aimed to evaluate the efficacy of oral famotidine in the prevention of HSRs in patients who received chemotherapy agents, particularly platinum-based and taxanes.</p><p><strong>Methods: </strong>A total of 426 patients who were treated with platinum-based agents or taxanes as part of their regimen were divided into two groups. The famotidine group, including 213 patients, received the standard premedication along with an oral dose of 40 mg famotidine the night before and 1 h prior to the chemotherapy session. The control group, also including 213 patients, received only the standard premedication without famotidine.</p><p><strong>Results: </strong>Based on the results of this study, six patients in the control group experienced HSRs with a range of varying severities. No HSRs were observed by any of the patients in the famotidine group (p-value = 0.022).</p><p><strong>Conclusion: </strong>Administration of oral famotidine is beneficial in preventing chemotherapy-induced HSRs.</p><p><strong>Clinical trial registration: </strong>It was also registered with the Iran Clinical Trial Centre under code IRCT20160310026998N13.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.14154","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Hypersensitivity reactions (HSRs), an unpredictable and sometimes harmful reaction, may hamper the effectiveness of chemotherapy and lead to the need for drug switching. The recall of ranitidine from the drug market due to the N-nitrosodimethylamine production necessitates the identification of a proper alternative for the prevention of HSRs. Our study aimed to evaluate the efficacy of oral famotidine in the prevention of HSRs in patients who received chemotherapy agents, particularly platinum-based and taxanes.

Methods: A total of 426 patients who were treated with platinum-based agents or taxanes as part of their regimen were divided into two groups. The famotidine group, including 213 patients, received the standard premedication along with an oral dose of 40 mg famotidine the night before and 1 h prior to the chemotherapy session. The control group, also including 213 patients, received only the standard premedication without famotidine.

Results: Based on the results of this study, six patients in the control group experienced HSRs with a range of varying severities. No HSRs were observed by any of the patients in the famotidine group (p-value = 0.022).

Conclusion: Administration of oral famotidine is beneficial in preventing chemotherapy-induced HSRs.

Clinical trial registration: It was also registered with the Iran Clinical Trial Centre under code IRCT20160310026998N13.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估口服法莫替丁对预防接受铂类药物或紫杉类药物治疗者过敏反应的影响
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.40
自引率
0.00%
发文量
175
审稿时长
6-12 weeks
期刊介绍: Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.
期刊最新文献
Physical Activity and Its Barriers During the First Year Following Breast Cancer Surgery. Availability and Characteristics of Support Groups for People With Head and Neck Cancer in Australia. Prognostic Value of CD133 and SOX2 Expression After Neoadjuvant Chemotherapy in Patients with Locally Advanced Gastric Cancer. Issue Information Unmet Need for Breast Cancer Screening Among South Asian Women in Victoria.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1